[go: up one dir, main page]

NO850521L - Fremgangsmaate for fremstilling av farmakologisk aktive diestere - Google Patents

Fremgangsmaate for fremstilling av farmakologisk aktive diestere

Info

Publication number
NO850521L
NO850521L NO850521A NO850521A NO850521L NO 850521 L NO850521 L NO 850521L NO 850521 A NO850521 A NO 850521A NO 850521 A NO850521 A NO 850521A NO 850521 L NO850521 L NO 850521L
Authority
NO
Norway
Prior art keywords
procedure
preparation
pharmacologically active
active diesters
diesters
Prior art date
Application number
NO850521A
Other languages
English (en)
Other versions
NO166123C (no
NO166123B (no
Inventor
Dante Nardi
Amedeo Leonardi
Gabriele Graziani
Giorgio Bianchi
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10556581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO850521(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of NO850521L publication Critical patent/NO850521L/no
Publication of NO166123B publication Critical patent/NO166123B/no
Publication of NO166123C publication Critical patent/NO166123C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
NO850521A 1984-02-14 1985-02-12 Analogifremgangsmaate for fremstilling av terapeutisk aktive asymmetriske diestere av dihydropyridindikarboksylsyrer. NO166123C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848403866A GB8403866D0 (en) 1984-02-14 1984-02-14 Diphenylalkylaminoalkyl esters

Publications (3)

Publication Number Publication Date
NO850521L true NO850521L (no) 1985-08-15
NO166123B NO166123B (no) 1991-02-25
NO166123C NO166123C (no) 1991-06-05

Family

ID=10556581

Family Applications (2)

Application Number Title Priority Date Filing Date
NO850521A NO166123C (no) 1984-02-14 1985-02-12 Analogifremgangsmaate for fremstilling av terapeutisk aktive asymmetriske diestere av dihydropyridindikarboksylsyrer.
NO2000011C NO2000011I1 (no) 1984-02-14 2000-10-17 Lercanidipin og farmasøytisk akseptable salter derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2000011C NO2000011I1 (no) 1984-02-14 2000-10-17 Lercanidipin og farmasøytisk akseptable salter derav

Country Status (29)

Country Link
US (3) US4705797A (no)
EP (1) EP0153016B1 (no)
JP (1) JPS60199874A (no)
KR (1) KR910005231B1 (no)
AR (1) AR240804A1 (no)
AT (1) ATE52772T1 (no)
AU (1) AU570534B2 (no)
BR (1) BR1101167A (no)
CA (1) CA1277666C (no)
DE (2) DE10199007I2 (no)
DK (1) DK160985C (no)
DZ (1) DZ748A1 (no)
EG (1) EG17772A (no)
ES (1) ES540385A0 (no)
FI (1) FI83954C (no)
GB (1) GB8403866D0 (no)
GR (1) GR850363B (no)
HU (1) HU194171B (no)
IE (1) IE57715B1 (no)
IL (1) IL74238A (no)
LU (1) LU90069I2 (no)
MX (1) MX156874A (no)
NL (1) NL970025I2 (no)
NO (2) NO166123C (no)
NZ (1) NZ210866A (no)
PH (1) PH20725A (no)
PT (1) PT79963B (no)
SG (1) SG48590G (no)
ZA (1) ZA85656B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
EP0220917B1 (en) * 1985-10-22 1991-01-30 Sanwa Kagaku Kenkyusho Co., Ltd. 1,4-dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
JPH02149563A (ja) * 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd 2−ハロエトキシカルボニル基を含有する1,4−ジヒドロピリジン誘導体の製造法
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
IT1279529B1 (it) * 1995-05-12 1997-12-16 Recordati Chem Pharm Procedimento di preparazione ed uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5851636A (en) * 1995-12-29 1998-12-22 Lantec Products, Inc. Ceramic packing with channels for thermal and catalytic beds
RU2200315C2 (ru) * 2001-05-25 2003-03-10 Чалкин Станислав Филиппович Устройство для анализа жидких сред люминесцентным методом
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011727A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
ITMI20011726A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
AP2501A (en) 2003-05-30 2012-10-22 Ranbaxy Lab Ltd Substituted pyrrole derivatives
WO2005107374A2 (en) * 2004-05-07 2005-11-17 Sun Pharmaceutical Industries Limited A process for the preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
KR100616276B1 (ko) * 2004-09-21 2006-08-28 일동제약주식회사 2,엔-디메틸-엔-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) * 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
IL165525A0 (en) * 2004-12-02 2006-01-15 Motivan Ltd Intermediates and a process for the manufacturing for antihypertensive dihydropyridine derivative suitable for pharmaceutical compositions
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR100638171B1 (ko) * 2005-03-25 2006-10-26 건일제약 주식회사 2,n-디메틸-n-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
DE602005017199D1 (de) * 2005-06-15 2009-11-26 Hetero Drugs Ltd Neues verfahren zur herstellung von lercanidipin
EP1940790B1 (en) * 2005-09-16 2015-09-02 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
WO2007054969A2 (en) * 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP2009513660A (ja) 2005-10-26 2009-04-02 旭化成ファーマ株式会社 肺動脈性高血圧の治療用併用療法におけるファスジル
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
ATE415389T1 (de) * 2006-05-24 2008-12-15 Cf Pharma Ltd Verfahren zur herstellung von lercanipidin
AU2007280407B2 (en) * 2006-08-04 2012-09-27 Recordati Ireland Limited Process for preparing amorphous lercanidipine hydrochloride
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
JP2010514753A (ja) * 2006-12-29 2010-05-06 ドンウ シンテック カンパニー リミテッド レルカニジピン塩酸塩の製造方法
KR100848935B1 (ko) 2007-05-16 2008-07-29 주식회사 대희화학 생체 촉매 효소를 이용한 광학 선택적 가수분해방법
EA027787B1 (ru) 2010-06-23 2017-09-29 Крка, Товарна Здравил, Д.Д., Ново Место Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
EA023996B1 (ru) 2010-12-24 2016-08-31 КРКА, д.д., НОВО МЕСТО Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацевтически приемлемые соли совместно с органической кислотой
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
KR101695582B1 (ko) 2013-04-17 2017-01-13 화이자 인코포레이티드 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
JPS5762257A (en) * 1980-10-03 1982-04-15 Yoshitomi Pharmaceut Ind Ltd 1,4-dihydropyridine-3,5-dicarboxylic acid ester or its salt
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
ATE50987T1 (de) * 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
NO854021L (no) * 1984-10-26 1986-04-28 Bayer Ag 1,4-dihydropyridin-hydroksyaminer og fremgangsmaate til fremstilling derav.
GB8503424D0 (en) * 1985-02-11 1985-03-13 Ici Plc Heterocyclic derivatives

Also Published As

Publication number Publication date
HU194171B (en) 1988-01-28
PT79963B (en) 1986-11-10
DK63085A (da) 1985-08-15
SG48590G (en) 1990-08-17
EP0153016A2 (en) 1985-08-28
DK160985B (da) 1991-05-13
CA1277666C (en) 1990-12-11
DE10199007I1 (de) 2001-04-12
NL970025I2 (nl) 1998-01-05
MX156874A (es) 1988-10-08
AU3868985A (en) 1985-09-12
NO2000011I1 (no) 2000-10-17
ATE52772T1 (de) 1990-06-15
US4705797A (en) 1987-11-10
JPH0517908B2 (no) 1993-03-10
DZ748A1 (fr) 2004-09-13
FI83954B (fi) 1991-06-14
AR240804A2 (es) 1991-02-28
PT79963A (en) 1985-03-01
NL970025I1 (nl) 1997-09-01
DE3577703D1 (de) 1990-06-21
DK63085D0 (da) 1985-02-12
KR850005826A (ko) 1985-09-26
GR850363B (no) 1986-02-06
FI850535A0 (fi) 1985-02-08
NZ210866A (en) 1988-07-28
EP0153016A3 (en) 1985-10-02
KR910005231B1 (ko) 1991-07-24
NO166123C (no) 1991-06-05
IL74238A0 (en) 1985-05-31
IL74238A (en) 1988-07-31
GB8403866D0 (en) 1984-03-21
ZA85656B (en) 1985-08-28
JPS60199874A (ja) 1985-10-09
FI83954C (fi) 1991-09-25
PH20725A (en) 1987-03-30
ES8602664A1 (es) 1985-11-16
EG17772A (en) 1991-08-30
HUT37399A (en) 1985-12-28
NO166123B (no) 1991-02-25
IE850280L (en) 1985-08-14
IE57715B1 (en) 1993-03-10
FI850535L (fi) 1985-08-15
AU570534B2 (en) 1988-03-17
LU90069I2 (fr) 1997-07-23
US4968832A (en) 1990-11-06
EP0153016B1 (en) 1990-05-16
DE10199007I2 (de) 2003-01-09
BR1101167A (pt) 2004-08-17
ES540385A0 (es) 1985-11-16
DK160985C (da) 1991-11-04
AR240804A1 (es) 1991-02-28
US4772621A (en) 1988-09-20

Similar Documents

Publication Publication Date Title
NO850521L (no) Fremgangsmaate for fremstilling av farmakologisk aktive diestere
NO171209C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfinanestere
NO164025C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
NO831679L (no) Fremgangsmaate for fremstilling av farmakologisk aktive 1,3-dioksan-5-yl-alkensyrer
NO172048C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazoler
NO162189C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazopyridiner.
NO162113C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolaminforbindelser.
NO851695L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-heteroaryl-tiazol-derivater
NO864879D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiasolforbindelser.
NO161497C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9a-aza-9a-homoerytromycin-derivater.
NO864110D0 (no) Fremgangsmaate for fremstilling av terapeutisk virksomme benzimidazolderivater.
NO852729L (no) Fremgangsmaate for fremstilling av terapeutisk virksomme benzimidazol- og benzotiazolderivater
NO862373D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tienopyridoner.
NO171592C (no) Fremgangsmaate for fremstilling av aktive cinnolin-derivater
NO854369L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater
NO169126C (no) Fremgangsmaate for fremstilling av n-formyl-alfa-aspartyl-fenylalanin
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
NO834729L (no) Fremgangsmaate for fremstilling av farmakologisk aktive tio-cefalosporiner
NO164172C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tricykliske tienokondenserte forbindelser.
NO162188C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinoliner.
NO170012C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzamider
FI89595B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2-(tioalkylamino)etyl-1H-imidazolderivat
NO168581C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive beta-methylen-thiofenethanaminer
NO160712C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-forbindelser.
NO168473C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylthiazoloner.